Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-I109V in chronic HBV and HCC
NCT05867056Phase 1Withdrawn
- Sponsor
- Immunocore
- Start
- Aug 2020
- Primary completion
- Sep 2024
- Modality
- Antibody Fragments, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 1, open-label trial of IMC-I109V in Chronic Hepatitis B (CHB) and hepatocellular carcinoma (HCC) (3 arms), sponsored by Immunocore. Primary endpoints: Incidence and treatment-emergent adverse events, Incidence of serious adverse events and 5 more. Planned start Aug 2020; status: withdrawn.
02
Drugs
IMC-I109V
03
Conditions
Chronic Hepatitis B (CHB)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05867056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867056.